XTLB

XTL Biopharmaceuticals Ltd.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$1.62

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %4.9 / %30

Non-compliant assets / Total market cap %0 / %30

Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.

Website

Analysis (Turkish): XTLB Hissesi Caiz mi, Helal mi? XTL Biopharmaceuticals Ltd. Katılım Analizi